Overview
Terrana Biosciences uses an AI-assisted platform to design RNA-based tools that improve plant health across a plant’s life cycle. Its products span from seed treatment to post-harvest and aim to enable heritable crop traits, starting with crop protection. The company differentiates itself by pairing RNA interventions with generative AI to create solutions that work across the plant’s entire lifecycle, potentially licensing technology or offering treated seeds and direct-to-farm services. The goal is to provide safe, scalable RNA-based tools that enhance crop protection and resilience across generations, expanding options beyond traditional genetics or chemical protections.
Work here?Claim your company
Simplify's take
What believers are saying
- Terrana showed proof of concept in tomatoes, corn, and soy by 2025.
- Flagship cited 15-plus products in development by October 2026.
- Rapp presented Terrana at Ai4 2026, signaling active recruiting and scientific visibility.
What critics are saying
- EPA has made no public determination on Terrana as of March 2026.
- Terrana remains pre-commercial, with no approved product and no field revenue.
- Synthetic RNA crop products face regulatory bottlenecks that can delay launch for years.
What makes Terrana Biosciences unique
- Flagship launched Terrana Biosciences in July 2025 with $50 million backing.
- Terrana uses native plant RNA and AI for non-genome-altering crop traits.
- Ryan Rapp said Terrana targets crop protection across plant lifecycles, including tomatoes, corn, soy.
Help us improve and share your feedback! Did you find this helpful?